Read more information about Lareb and our research about adverse drugs reactions (ADRs)
Home
Actueel
-
24 oktober 2024
Fever and mebendazole
Until July 2024, the Netherlands Pharmacovigilance Centre Lareb received 23 reports of fever following use of mebendazole. Fever is not a known side effect of mebendazole. Fever is mentioned in the pr...
-
18 september 2024
Highlighting challenges in monitoring herbal products and presenting universal recommendations
Lareb conducted a study comprised of semi-structured interviews in order to explore the current landscape of herbal pharmacovigilance and to offer recommendations for best practices to enhance the saf...
-
27 juni 2024
Prolonged duration of COVID-19 vaccine-induced lymphadenopathy
The Netherlands Pharmacovigilance Centre Lareb has received reports of enlarged lymph nodes after COVID-19 vaccination that do not disappear within the expected 1 to 2 weeks. In some cases, the lymph ...
View reports
Enter at least the first four letters of the name of the medicine you are looking for in the first search bar. Then choose the right medicine.
If applicable, then select the correct dosage form in the second bar, such as: effervescent tablet, chewable tablet, suppository or oral solution.
What does Lareb do
-
News
Lareb shares information about adverse drug reactions (ADR’s) and other news about safe use of medicines. View all news items on our news items page. -
Teratology Information Service
The Teratology Information Service (TIS) is the knowledge centre of Lareb on safety of drugs used before and during pregnancy and during breastfeeding -
Research activities of Lareb
We continuously conduct research with questionnaires. This way, we learn more about known ADR's of medicines and vaccines and we learn to recognize these earlier.